

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai HeartCare Medical Technology  
Corporation Limited**

**上海心瑋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6609)**

**ANNOUNCEMENT IN RELATION  
TO COMPLETION OF THE ISSUANCE OF  
DOMESTIC SHARES UNDER SPECIFIC MANDATE**

Reference is made to the announcements of Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”) dated December 12, 2025, January 16, 2026 and May 21, 2026 (the “**Announcements**”) and the circular dated December 31, 2025 (the “**Circular**”) in relation to, among other things, the proposed issue of Domestic Shares under the Specific Mandate. Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the Announcements and the Circular.

The Board is pleased to announce that the Company received the share registration certificate dated June 29, 2026 issued by China Securities Depository and Clearing Corporation Limited in respect of the Subscription and the issuance of Subscription Shares at the price of HK\$45.00 per Subscription Share, pursuant to which, 1,000,000 Domestic Shares have been issued as fully paid to the Subscriber, and the Subscription and the issuance of Subscription Shares has been completed.

Therefore, immediately after the completion of the Subscription and the issuance of Subscription Shares, the total number of issued shares of the Company was 38,862,008 Shares (excluding treasury shares), comprising 8,268,604 Unlisted Shares and 30,593,404 H Shares (excluding treasury shares). As at the date of this announcement, 972,400 H Shares were treasury shares held or deposited with the Central Clearing and Settlement System operated by Hong Kong Securities Clearing Company Limited.

The gross proceeds from the Subscription amounted to HK\$45.0 million (equivalent to approximately RMB40.85 million), and the net proceeds arising from the Subscription, after deducting all relevant expenses incidental to the Subscription, amounted to approximately RMB39.66 million, which is intended to be used for investments, mergers and acquisitions opportunities in the medical devices industry, including (i) new opportunities and increasing investment in the Company's existing investee companies within the neurointerventional space; (ii) new merger and acquisition, business development opportunities in the vascular intervention space, especially in sourcing suitable overseas acquisition targets, which are currently expected to be fully utilized by December 31, 2028.

The shareholding structure of the Company immediately before and immediately after the completion of the Subscription and the issuance of Subscription Shares is set out as follows:

|                                                                               | Immediately before completion of the Subscription |                                      |                         |                                      | Immediately after completion of the Subscription |                                      |                         |                                      |
|-------------------------------------------------------------------------------|---------------------------------------------------|--------------------------------------|-------------------------|--------------------------------------|--------------------------------------------------|--------------------------------------|-------------------------|--------------------------------------|
|                                                                               | Number of Shares                                  | Approximate % of total issued Shares | Number of H Shares only | Approximate % of total issued Shares | Number of Shares                                 | Approximate % of total issued Shares | Number of H Shares only | Approximate % of total issued Shares |
| <b>Core Connected Persons of the Company</b>                                  |                                                   |                                      |                         |                                      |                                                  |                                      |                         |                                      |
| Mr. Wang Guohui <sup>1</sup>                                                  | 8,886,847                                         | 23.47%                               | 5,698,737               | 15.05%                               | 8,886,847                                        | 22.87%                               | 5,698,737               | 14.66%                               |
| Ms. Zhang Kun <sup>2</sup>                                                    | 2,776,176                                         | 7.33%                                | 1,209,688               | 3.19%                                | 2,776,176                                        | 7.14%                                | 1,209,688               | 3.11%                                |
| <b>Subtotal</b>                                                               | <b>11,663,023</b>                                 | <b>30.80%</b>                        | <b>6,908,425</b>        | <b>18.25%</b>                        | <b>11,663,023</b>                                | <b>30.01%</b>                        | <b>6,908,425</b>        | <b>17.78%</b>                        |
| <b>Other public Shareholders (which are counted towards the public float)</b> |                                                   |                                      |                         |                                      |                                                  |                                      |                         |                                      |
| Mr. Zhang Han                                                                 | —                                                 | —                                    | —                       | —                                    | 1,000,000                                        | 2.57%                                | —                       | —                                    |
| Other public Shareholders                                                     | 26,198,985                                        | 69.20%                               | 23,684,979              | 62.56%                               | 26,198,985                                       | 67.42%                               | 23,684,979              | 60.95%                               |
| <b>Subtotal</b>                                                               | <b>26,198,985</b>                                 | <b>69.20%</b>                        | <b>23,684,979</b>       | <b>62.56%</b>                        | <b>27,198,985</b>                                | <b>69.99%</b>                        | <b>23,684,979</b>       | <b>60.95%</b>                        |
| <b>Total</b>                                                                  | <b>37,862,008</b>                                 | <b>100%</b>                          | <b>30,593,404</b>       | <b>80.80%</b>                        | <b>38,862,008</b>                                | <b>100%</b>                          | <b>30,593,404</b>       | <b>78.72%</b>                        |

Notes:

- (1) The Shares that Mr. Wang Guohui is regarded as having an interest in, includes his interest via Ningbo Weizheng Self-Owned Capital Investment Partnership (LP) (寧波瑋鉦自有資金投資合夥企業(有限合夥)) (“**Weizheng Investment**”), Shanghai Zandaqian Enterprise Management Consulting Center (上海贊大乾企業管理諮詢中心) (“**Shanghai Zandaqian**”), Ningbo Meishan Bonded Port Area Kaiyuan Investment Management Partnership (LP) (寧波梅山保稅港區楷遠投資管理合夥企業(有限合夥)) (“**Kaiyuan Investment**”), Ningbo Weiyun Self-Owned Capital Investment Partnership (LP) (寧波瑋鋆自有資金投資合夥企業(有限合夥)) (“**Weiyun Investment**”) and Ningbo Weiyu Self-Owned Capital Investment Partnership (LP) (寧波瑋鉦自有資金投資合夥企業(有限合夥)) (“**Weiyu Investment**”).

- (2) The Shares that Ms. Zhang Kun is regarded as having an interest in, includes her interest via her spouse, Mr. Chai Yanpeng, and the entity controlled by Mr. Chai Yanpeng, Ningbo Tongchuangsuwei Investment Partnership (LP) (寧波同創速維投資合夥企業(有限合夥)) (“**Tongchuangsuwei**”).
- (3) The aggregate of the percentage figures in the above table may not add up to the sub-total or total percentage figures due to rounding of the percentage figures to two decimal places. The shareholding presented herein has not taken into account treasury shares of the Company.

Upon completion of the Subscription and the issuance of Subscription Shares, the number of H Shares held by the public remains unchanged and represents approximately 77.42% of the total number of H shares of the Company in issue (excluding treasury shares), which satisfies the public float requirements under Rule 8.08(1) of the Listing Rules.

By order of the Board  
**Shanghai HeartCare Medical Technology Corporation Limited**  
**WANG Guohui**  
*Chairman of the Board*

Shanghai, June 29, 2026

*As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.*